Login / Signup

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.

Paul M BarrStephen D SmithMark J RoschewskiSusan M O'BrienJeff P SharmanJason M MelearPriti PatelRoser CalvoHelen YangStephen E Spurgeon
Published in: Leukemia & lymphoma (2022)
Keyphrases
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • multiple myeloma
  • hodgkin lymphoma
  • open label
  • diffuse large b cell lymphoma
  • double blind
  • placebo controlled
  • randomized controlled trial
  • clinical trial